Preferred
(EDT)
Other
Antibodies as Drugs for COVID‑19
Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days
9:00 AM - 9:15 AM EST
Wednesday, January 13, 2021Speaker
Bo Barnhart, PhD
Abcellera Biologics Inc.
Antibodies as Drugs for COVID‑19
Rapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases
9:15 AM - 9:30 AM EST
Wednesday, January 13, 2021Speaker
Christos Kyratsous, PhD
Regeneron Pharmaceuticals Inc
Antibodies as Drugs for COVID‑19
Cross‑Neutralization of SARS‑CoV‑2 by a Human Monoclonal SARS‑CoV Antibody
9:30 AM - 9:45 AM EST
Wednesday, January 13, 2021Speaker
Davide Corti, PhD
Humabs BioMed SA
Antibodies as Drugs for COVID‑19
Neutralizing Antibodies—The Hope for a COVID‑19 Cure
9:45 AM - 10:00 AM EST
Wednesday, January 13, 2021Speaker
X. Sunney Xie, PhD
Peking University
Antibodies as Drugs for COVID‑19
Coffee Break
10:00 AM - 10:25 AM EST
Wednesday, January 13, 2021Antibodies as Drugs for COVID‑19
Human Neutralizing Antibodies Elicited by SARS‑CoV‑2 Infection
10:25 AM - 10:40 AM EST
Wednesday, January 13, 2021Speaker
Linqi Zhang, PhD
Tsinghua University
Antibodies as Drugs for COVID‑19
When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19
10:40 AM - 10:55 AM EST
Wednesday, January 13, 2021Speaker
Xavier Saelens, PhD
Ghent University
Antibodies as Drugs for COVID‑19
Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates
10:55 AM - 11:10 AM EST
Wednesday, January 13, 2021Speaker
Michael Stumpp, PhD
Molecular Partners
Antibodies as Drugs for COVID‑19
Therapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection
11:10 AM - 11:25 AM EST
Wednesday, January 13, 2021Speaker
Michael Ison, MD
Northwestern/Celltrion, Inc.
Antibodies as Drugs for COVID‑19
Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors
11:25 AM - 11:40 AM EST
Wednesday, January 13, 2021Speaker
Natalia Freund, PhD
Tel Aviv University
